IGC Pharma Inc (IGC)
0.43
-0.01
(-2.05%)
USD |
NYAM |
Apr 25, 16:00
0.422
-0.01
(-1.86%)
After-Hours: 07:02
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 27.41M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 29.60% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 19.82 |
| Price to Book Value | 3.027 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0152 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 97.77% |
Profile
| IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer’s. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps. |
| URL | https://www.igcinc.us |
| Investor Relations URL | N/A |
| HQ State/Province | Maryland |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Aug. 14, 2024 (est.) |
| Last Earnings Release | Feb. 14, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer’s. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps. |
| URL | https://www.igcinc.us |
| Investor Relations URL | N/A |
| HQ State/Province | Maryland |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Aug. 14, 2024 (est.) |
| Last Earnings Release | Feb. 14, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |